[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Energenx Medical LTD.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,61],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100572881","clinical-trial-to-evaluate-the-efficacy-and-safety-of-pulsed-electric-field-ablation-devices-in-the-treatment-of-lung-tumors-100572881",false,"NCT06739031","Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors","A Multi-center, Single-group Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field (PEF) Ablation Devices in the Treatment of Lung Tumors","Inclusion criteria (all requirements must be met at the same time):\n\n1\\. Age ≥ 18 years old; 2. Pathological diagnosis of non-small cell lung cancer, with the maximum diameter of the tumor ≤ 3 cm and the number ≤ 3; 3. ECOG score ≤ 2 points; 5. According to the evaluation of the researcher, it is technically feasible to perform ablation treatment on the lesion; 6. The subject agrees to receive ablation treatment and signs the informed consent form.\n\nExclusion criteria (if any of the above conditions are met, the patient will be excluded):\n\n1. The subject cannot tolerate or refuses general anesthesia;\n2. Has a history of severe allergic reactions;\n3. Has contraindications to bronchoscopy or refuses bronchoscopy;\n\n5\\. Has active implants in the chest cavity or metal implants in the lung to be treated; 6. Uncorrectable coagulation abnormalities (INR\\>1.5 or APTT\\>1.5 ULN), with bleeding tendency; anticoagulant therapy and\u002For antiplatelet drugs are discontinued before ablation for no longer than the prescribed safety period; platelets \\\u003C50×10\\^9\u002FL; 7. Severe liver and kidney dysfunction, assessed by the researchers as unsuitable for inclusion; 8. Accompanied by infectious diseases that cannot be effectively controlled; 9. Subjects with other severe lung diseases (including severe interstitial pneumonia, pulmonary fibrosis, pulmonary fibrosis combined with emphysema, atelectasis, etc.), assessed by the researchers as unsuitable for inclusion 10. Acute cardiovascular and cerebrovascular accidents such as acute cerebral infarction, acute coronary syndrome, etc. within 3 months; 11. Subjects with severe cardiac dysfunction; history of severe arrhythmias in the past 2 years, including rapid atrial arrhythmias, any rapid ventricular arrhythmias; history of II degree type II or III degree atrioventricular block; and sinus bradycardia with a heart rate of less than 45 beats per minute, etc.; 12. Subjects have participated in or are participating in other clinical trials within three months; 13. Pregnant, lactating women, or women who plan to become pregnant during the study; 14. Subjects determined by the researchers to have other conditions that are unsuitable for inclusion.","ALL","18 Years",{"count":19,"type":20},126,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to verify the efficacy and safety of pulsed electric field (PEF) treatment of early-stage unreseectable non-small cell lung cancer(NSCLC) patients.\n\nThe main questions it aims to answer are:\n\n* Safety of PEF treatment of early-stage unreseectable NSCLC patients.\n* Locoregional control of ablated lesions.\n* Survival and quality of life assessment of early-stage unreseectable NSCLC patients.",[26],"NSCLC","RECRUITING","2026-08-20",{"date":30,"type":31},"2026-08-21","ACTUAL",{"date":33,"type":31},"2024-12-25",{"date":35,"type":20},"2027-08-25",{"name":37,"class":38},"Energenx Medical LTD.","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":58,"leadSponsor":60,"locationsCount":39},"100574250","safety-and-efficacy-study-of-pulsed-electric-field-pef-therapy-in-patients-with-advanced-or-unresectable-esophageal-squamous-cell-carcinoma-100574250","NCT06756841","Safety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma","A Single-arm Clinical Trial to Explore the Safety and Efficacy of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Aged 20 years or older when signing the informed consent form.\n2. Able to provide written informed consent, and understand and follow the study requirements and assessment schedule.\n3. Screening period tumor patients ECOG performance status score of 0 or 1.\n4. Laboratory test data within 7 days before the planned PEF treatment date during the screening period must meet the following standards.\n\n   * Neutrophil count (ANC) ≥1500 cells\u002Fmm3\n   * Platelet count ≥100,000 cells\u002Fmm3\n   * Hemoglobin ≥9 g\u002FdL or ≥5.6 mmol\u002FL\n   * Serum total bilirubin ≤ 1.5 x ULN.\n5. Females of childbearing potential must have a negative serum pregnancy test at screening and be willing to undergo additional pregnancy testing during the study.\n\nExclusion Criteria:\n\n1. Subjects with active respiratory tract infection who need antibiotic or antiviral treatment;\n2. Patients with locally advanced ESCC whose tumors can be surgically removed by the investigator or can be potentially cured by radical chemoradiotherapy according to the judgment of local investigators.\n3. Patients with esophageal lesions that severely invade adjacent organs (esophagus\u002Fbronchus or esophagus\u002Faorta) and are assessed as high-risk esophageal leakage\u002Ffistula by the investigator.\n4. Evidence of complete esophageal obstruction that is not suitable for treatment, and gastroscopy cannot be performed.\n5. Patients with a history of esophageal stent implantation for esophageal obstruction;\n6. Patients with a history of gastrointestinal bleeding in the past 4 weeks, or gastroscopy indicates a high risk of tumor ulcer bleeding.\n7. Patients with obstruction caused by anastomotic stenosis without esophageal primary lesions after previous esophageal cancer surgery.\n8. Patients with active leptomeningeal disease or brain metastasis.\n9. Any active malignant tumor within 5 years before screening.\n10. Subjects have undergone metal implantation surgery such as esophageal stents and airway stents. Or the patient has an implantable cardioverter-defibrillator, pacemaker or other implantable electronic device.\n11. Patients with positive HIV test.\n12. Subjects are currently participating in other research clinical trials;\n13. Subjects who are considered by the investigator to have other high-risk conditions and are not suitable for gastroscopy and surgery;\n14. Subjects who have adverse events that have not yet returned to baseline or stable levels due to previous anti-tumor treatment, except for adverse events that do not pose safety risks (such as hair loss and abnormal values of specific laboratory tests)","20 Years",{"count":49,"type":20},10,[23],"The goal of this clinical trial is to verify the safety and clinical benefit of pulsed electric field (PEF) treatment of advanced or unresectable esophageal squamous cell carcinoma patients.\n\nThe main questions it aims to answer are:\n\n* Safety and feasibility of PEF treatment of patients with advanced or unresectable esophageal squamous cell carcinoma.\n* Locoregional control of ablated lesions and quality of life assessment.\n* Local and peripheral immunoregulation effect.",[53],"Esophageal Cancer","NOT_YET_RECRUITING",{"date":56,"type":31},"2025-01-03",{"date":33,"type":20},{"date":59,"type":20},"2026-07-31",{"name":37,"class":38},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":70,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":39},"100515118","trial-of-pulsed-electric-field-therapy-in-patients-with-late-stage-non-small-cell-lung-cancer-100515118","NCT05987345","Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer","Safety and Clinical Efficacy Evaluation of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Patients over 22 years old with pathologically confirmed non-small cell lung cancer stage III-IV.\n2. Patients received first-line anti PD-1 immunotherapy and had disease progression.\n3. Lesions to be ablated must be ≤ 3cm in longest diameter(LD).\n\n   \\* The leison to be ablated can be ≤ 5cm in LD, if evaluated as possible with multiple energy delivery in a single session.\n4. More than one measurable lesion according to RECIST 1.1 except PEF targeted lesions.\n5. Eastern Cooperative Oncology Group(ECOG) performance status 0-1\n6. Life expectancy ≥3 months\n7. Fully understand the treatment plan and sign the informed consent form voluntarily.\n\nExclusion Criteria:\n\n1. Patients should be excluded if they received surgery within 30 days.\n2. Patients should be excluded if they received any form of local treatment within 30 days.\n3. Accompanied by uncontrolled metastasis of the central nervous system.\n4. Have a history of severe adverse reactions to ICI.\n5. With uncontrolled immune system diseases or being treated with immunosuppressants.\n6. Severe abnormality of liver and kidney function, which was evaluated by the researchers as unsuitable for admission.\n7. Patients with abnormal blood coagulation and antiplatelet therapy due to cardiovascular and cerebrovascular diseases should be discontinued one week before PEF treatment according to the evaluation of clinicians.\n8. Accompanied by infectious diseases that cannot be effectively controlled.\n9. Suffered from other severe lung diseases (including interstitial pneumonia, pulmonary fibrosis, pulmonary fibrosis with emphysema, atelectasis, etc.)\n10. Patients who had severe cardiac dysfunction and had a history of arrhythmias in the past 2 years, including rapid atrial arrhythmias, any rapid ventricular arrhythmias, a history of degree II or III atrioventricular block, and sinus bradycardia with a heart rate of less than 45 beats per minute.\n11. Patients who are participating in other clinical trials.\n12. With a cardiac pacemaker or metal implant in the chest.\n13. Women who are pregnant or lactating, or who plan to become pregnant during the study.\n14. The researchers determined that there were other conditions in which patients were not suitable for enrollment.\n15. Patients who have a history of receiving non-first-line anti PD-1 immunotherapy.","22 Years",{"count":49,"type":20},[23],"The goal of this clinical trial is to verify the safety and clinical benefit of pulsed electric field(PEF) treatment of metastatic non-small cell lung cancer(NSCLC) patients with acquired resistance to anti programmed cell death protein 1(PD-1) monoclonal antibody therapy.\n\nThe main questions it aims to answer are:\n\n* Safety of PEF treatment of metastatic NSCLC patients.\n* Control of ablated and other targeted lesions.\n* Local and peripheral immunoregulation effect. PEF energy will be delivered to preselected lesions of participants, then anti PD-1 will be routinely administrated if no adverse event(AE)\u002Fserious adverse event(SAE) which need medical intervention occurs.",[26],[26,74,75],"PEF","Immune Checkpoint Inhibitor(ICI)","2024-07-18",{"date":78,"type":31},"2024-07-22",{"date":80,"type":31},"2023-07-06",{"date":82,"type":20},"2024-07-31",{"name":37,"class":38},""]